Mirapex 1 mg 30 tablets — Made in Germany — Free Delivery

It is necessary to evaluate the patient's response to treatment after 3 months and reconsider the need to continue therapy. If treatment is interrupted for more than a few days, restart at the dose indicated above.

Termination of treatment. Since the daily dose for the treatment of restless legs syndrome does not exceed 0.75 mg, Mirapex® can be discontinued without a gradual dose reduction. In a 26-week, placebo-controlled clinical trial, relapse of restless legs syndrome symptoms (increased severity of symptoms from baseline) was observed in 10% of patients (14 of 135 patients) after sudden discontinuation of pramipexole. This effect was observed for all doses.

Method of use - tablets must be taken orally with water, with or without food.

The effect on pregnancy and lactation in humans has not been studied. "Mirapex®" can be used by pregnant women only if the potential benefit outweighs the potential risk to the fetus.

Since Mirapex® treatment suppresses prolactin secretion, a decrease in lactation is possible. Excretion of Mirapex® into breast milk has not been studied in women. This preparation is not recommended for women who are breastfeeding. If the use of Mirapex® cannot be avoided, breastfeeding should be discontinued.

Parkinson's disease. The safety and efficacy of Mirapex® in children (under 18 years of age) have not been established. There is no justification for the use of Mirapex® in children with Parkinson's disease.

Restless legs syndrome. The use of Mirapex® is not recommended for children (under the age of 18 years) due to insufficient data on safety and efficacy.

Tourette syndrome. Mirapex® should not be used in children (under 18 years of age) with Tourette's syndrome due to the negative benefit/risk ratio for this disease.

"Mirapex®" may have a significant effect on the ability to drive vehicles or work with mechanisms. You may experience hallucinations or drowsiness.

Patients with drowsiness and / or episodes of a sudden attack of drowsiness should refrain from driving and potentially hazardous activities when impaired attention increases the risk of serious injury or death when using Mirapex®.

There is no clinical experience of significant overdose. Expected side effects associated with the pharmacodynamic profile of a dopamine agonist include nausea, vomiting, hyperkinesia, hallucinations, agitation, and hypotension. An antidote for dopamine agonist overdose has not been established. In case of signs of excitation of the central nervous system, antipsychotics can be prescribed. Treatment of overdose patients may require general supportive measures along with gastric lavage, fluid administration, activated charcoal, and electrocardiogram monitoring.

Most adverse reactions are usually observed at the beginning of therapy, a significant proportion of them disappear even if therapy is continued.

In patients with Parkinson's disease treated with pramipexole compared with placebo, nausea, dyskinesia, arterial hypotension, dizziness, drowsiness, insomnia, constipation, hallucinations, headache and fatigue were common (≥ 5%) adverse reactions.